RATIONALE: Characterization of bacterial populations in infectious respiratory diseases will provide improved understanding of the relationship between the lung microbiota, disease pathogenesis, and treatment outcomes. OBJECTIVES: To comprehensively define lung microbiota composition during stable disease and exacerbation in patients with bronchiectasis. METHODS: Sputum was collected from patients when clinically stable and before and after completion of antibiotic treatment of exacerbations. Bacterial abundance and community composition were analyzed using anaerobic culture and 16S rDNA pyrosequencing. MEASUREMENTS AND MAIN RESULTS: In clinically stable patients, aerobic and anaerobic bacteria were detected in 40 of 40 (100%) and 33 of 40 (83%) sputum samples, respectively. The dominant organisms cultured were Pseudomonas aeruginosa (n = 10 patients), Haemophilus influenzae (n = 12), Prevotella (n = 18), and Veillonella (n = 13). Pyrosequencing generated more than 150,000 sequences, representing 113 distinct microbial taxa; the majority of observed community richness resulted from taxa present in low abundance with similar patterns of phyla distribution in clinically stable patients and patients at the onset of exacerbation. After treatment of exacerbation, there was no change in total (P = 0.925), aerobic (P = 0.917), or anaerobic (P = 0.683) load and only a limited shift in community composition. Agreement for detection of bacteria by culture and pyrosequencing was good for aerobic bacteria such as P. aeruginosa (κ = 0.84) but poorer for other genera including anaerobes. Lack of agreement was largely due to bacteria being detected by pyrosequencing but not by culture. CONCLUSIONS: A complex microbiota is present in the lungs of patients with bronchiectasis and remains stable through treatment of exacerbations, suggesting that changes in microbiota composition do not account for exacerbations.
RATIONALE: Characterization of bacterial populations in infectious respiratory diseases will provide improved understanding of the relationship between the lung microbiota, disease pathogenesis, and treatment outcomes. OBJECTIVES: To comprehensively define lung microbiota composition during stable disease and exacerbation in patients with bronchiectasis. METHODS: Sputum was collected from patients when clinically stable and before and after completion of antibiotic treatment of exacerbations. Bacterial abundance and community composition were analyzed using anaerobic culture and 16S rDNA pyrosequencing. MEASUREMENTS AND MAIN RESULTS: In clinically stable patients, aerobic and anaerobic bacteria were detected in 40 of 40 (100%) and 33 of 40 (83%) sputum samples, respectively. The dominant organisms cultured were Pseudomonas aeruginosa (n = 10 patients), Haemophilus influenzae (n = 12), Prevotella (n = 18), and Veillonella (n = 13). Pyrosequencing generated more than 150,000 sequences, representing 113 distinct microbial taxa; the majority of observed community richness resulted from taxa present in low abundance with similar patterns of phyla distribution in clinically stable patients and patients at the onset of exacerbation. After treatment of exacerbation, there was no change in total (P = 0.925), aerobic (P = 0.917), or anaerobic (P = 0.683) load and only a limited shift in community composition. Agreement for detection of bacteria by culture and pyrosequencing was good for aerobic bacteria such as P. aeruginosa (κ = 0.84) but poorer for other genera including anaerobes. Lack of agreement was largely due to bacteria being detected by pyrosequencing but not by culture. CONCLUSIONS: A complex microbiota is present in the lungs of patients with bronchiectasis and remains stable through treatment of exacerbations, suggesting that changes in microbiota composition do not account for exacerbations.
Authors: Christopher D Sibley; Michael D Parkins; Harvey R Rabin; Kangmin Duan; Jens C Norgaard; Michael G Surette Journal: Proc Natl Acad Sci U S A Date: 2008-09-23 Impact factor: 11.205
Authors: Michael J Cox; Martin Allgaier; Byron Taylor; Marshall S Baek; Yvonne J Huang; Rebecca A Daly; Ulas Karaoz; Gary L Andersen; Ronald Brown; Kei E Fujimura; Brian Wu; Diem Tran; Jonathan Koff; Mary Ellen Kleinhenz; Dennis Nielson; Eoin L Brodie; Susan V Lynch Journal: PLoS One Date: 2010-06-23 Impact factor: 3.240
Authors: Karen S McCoy; Alexandra L Quittner; Christopher M Oermann; Ronald L Gibson; George Z Retsch-Bogart; A Bruce Montgomery Journal: Am J Respir Crit Care Med Date: 2008-07-24 Impact factor: 21.405
Authors: D Worlitzsch; C Rintelen; K Böhm; B Wollschläger; N Merkel; M Borneff-Lipp; G Döring Journal: Clin Microbiol Infect Date: 2009-01-22 Impact factor: 8.067
Authors: Markus Hilty; Conor Burke; Helder Pedro; Paul Cardenas; Andy Bush; Cara Bossley; Jane Davies; Aaron Ervine; Len Poulter; Lior Pachter; Miriam F Moffatt; William O C Cookson Journal: PLoS One Date: 2010-01-05 Impact factor: 3.240
Authors: Geraint B Rogers; Thomas W V Daniels; Andrew Tuck; Mary P Carroll; Gary J Connett; Gondi J P David; Kenneth D Bruce Journal: BMC Pulm Med Date: 2009-04-15 Impact factor: 3.317
Authors: Bianca Harris; Sejal M Morjaria; Eric R Littmann; Alexander I Geyer; Diane E Stover; Juliet N Barker; Sergio A Giralt; Ying Taur; Eric G Pamer Journal: Am J Respir Crit Care Med Date: 2016-08-15 Impact factor: 21.405
Authors: Leopoldo N Segal; Jose C Clemente; Jun-Chieh J Tsay; Sergei B Koralov; Brian C Keller; Benjamin G Wu; Yonghua Li; Nan Shen; Elodie Ghedin; Alison Morris; Phillip Diaz; Laurence Huang; William R Wikoff; Carles Ubeda; Alejandro Artacho; William N Rom; Daniel H Sterman; Ronald G Collman; Martin J Blaser; Michael D Weiden Journal: Nat Microbiol Date: 2016-04-04 Impact factor: 17.745